Types of Sensor Systems

Here are the common types of glucose-sensor systems used Nov 2025:

  1. Real-Time Continuous Glucose Monitoring (rtCGM)

These systems continuously monitor glucose levels (in interstitial fluid) every few minutes, automatically send data to a receiver/smartphone/insulin pump, and often include alerts for highs/lows. (Cleveland Clinic)
Characteristics:

  • Sensor is inserted under the skin (in sub-cutaneous tissue). (Cleveland Clinic)
  • Transmitter sends readings to receiver or smartphone. (Wikipedia)
  • Provides real-time trends (rising/falling) and often alarms. (ADCES)

Advantages:

  • Gives a much more complete picture of glucose levels throughout day & night. (ADCES)
  • Helps identify trends/variability, not just single point measurements. (Diabetes Qualified)
  • Alarms can warn of impending hypoglycaemia/hyperglycaemia. (Diabetes Qualified)
  • Reduces the need for frequent finger-stick tests (though they may still be needed). (Cleveland Clinic)

Disadvantages:

  • The measurement is of interstitial fluid, not direct blood glucose; there can be a lag (often ~5-10 minutes) between blood glucose changes and sensor reading. (diabinfo.de)
  • Accuracy may be lower at very low or very high glucose levels; sometimes confirmation via finger-stick is recommended. (diabetes.org.uk)
  • Cost is higher (device + consumables + sensors + transmitter). (PMC)
  • Wearing a sensor and transmitter may cause physical/skin issues or psychological burden (alerts, data overload). (International Diabetes Federation)

2. Flash Glucose Monitoring (FGM) / Intermittent Scanning CGM (iscCGM)

These are variants where the sensor is worn, but the user must manually scan the sensor (e.g., with a reader or smartphone) to get a reading, instead of continuous push-updates and often without full alarm functionality. (Some newer FGM systems do include alarms.) (Wikipedia)
Characteristics:

  • Sensor is placed under skin; user scans to read glucose & trends.
  • May provide data retrospectively (e.g., last 8 hours) rather than live continuous push. (Wikipedia)
  • Usually fewer alarms (depending on model), maybe lower cost.

Advantages:

  • Less burden of continuous alarms/alerts (for users who find that stressful).
  • Generally simpler system; user initiates scan when desired.
  • May be more affordable than full rtCGM.
  • Good option for people who want improved glucose insight but maybe don’t need full real‐time alarm system.

Disadvantages:

  • Doesn’t always provide automatic alarms (or as robust alert functions) for low/high glucose.
  • Because user must scan, there can be gaps in data or missed events (especially during sleep).
  • Still subject to lag effect (interstitial vs blood) and possibly lower accuracy at extremes.
  • Some benefit (though less than rtCGM) in terms of predicting hypoglycaemia/hyperglycaemia.

3. Implantable / Long-Term Sensors

Some newer sensor systems are implanted (or semi-implanted) under the skin for extended wear (weeks to months) and use more advanced sensor technologies. (These are less common in everyday use, more in advanced/clinical settings). (Wikipedia)
Characteristics:

  • Sensor may be placed under skin (rather than just on surface) for longer duration.
  • May reduce need for frequent sensor changes.

Advantages:

  • Fewer sensor-changes → less insertion burden.
  • Potentially more stable sensor placement → possibly better comfort or convenience.

Disadvantages:

  • Insertion may need minor procedure.
  • If something fails, replacement is more complex.
  • May still carry same limitations (lag, accuracy extremes, cost).
  • Availability/approval may be more limited in some regions.

General Advantages & Disadvantages

General advantages of sensor systems (especially compared with just finger-stick tests):

  • More frequent data → better ability to detect trends, fluctuations, night‐time excursions. (ADCES)
  • Ability to catch/alert for low glucose levels (which are dangerous) earlier. (diabinfo.de)
  • Potential for improved glucose control (time in target range) when used appropriately. (PMC)
  • Improved lifestyle freedom (less frequent finger-sticks, more insight into how meals/exercise/stress affect glucose). (Diabetes Qualified)

General disadvantages/considerations:

  • Cost: Sensors + transmitters + possibly subscriptions can add up. (PMC)
  • Accuracy issues: Especially at the extremes of glucose levels, during rapid change, or when the sensor site is compressed, etc. The lag between interstitial fluid glucose and blood glucose is a factor. (diabinfo.de)
  • Data overload: Some users may feel overwhelmed by continuous data, alarms, trends. May increase anxiety rather than relieve it. (International Diabetes Federation)
  • Wearability/adhesion/skin issues: Sensor sites may irritate skin, adhesives may fail, sensor may dislodge or give erroneous readings due to pressure or movement. (Wikipedia)
  • Not a complete replacement for finger-stick tests in many cases (especially when making insulin dosing decisions based on sensor values). (ADCES)
  • Regulatory/availability issues: Some systems may not be available/approved in all countries; reimbursement and support vary.
  • Need for user education and consistent use: To get full benefit, users need to understand sensor data (trends, what to do with alerts).

How to Choose / Match to Patient Needs

When selecting between sensor systems (rtCGM vs FGM vs implantable), consider the following factors:

  • Risk of hypoglycaemia or variability: If someone is prone to frequent lows (hypoglycaemia) or has highly variable glucose, an rtCGM with alarms may be more beneficial.
  • Lifestyle and preferences: If you dislike frequent alarms or want simpler monitoring, FGM/iscCGM may be acceptable. If you are very active, travel, etc., wearability, sensor adhesion/comfort matter.
  • Cost / reimbursement / country availability: Check what is covered in your country (Germany/EU/India) and whether supplies are available locally.
  • Technical ability & willingness: Some systems require more involvement (e.g., reviewing data, responding to alerts). Consider whether you want “more hands-on” or “less burden”.
  • Sensor wear duration & convenience: Longer-wear sensors reduce insertion burden. If you prefer fewer changes, implantable type may be attractive (if available).
  • Integration with insulin pump / closed-loop system: If you use or plan to use an insulin pump or a hybrid/automated system, you’ll want a sensor that integrates with that pump.
  • Accuracy in your conditions: Consider how your lifestyle (exercise, compression of sensor site, unusual schedules) might affect sensor performance.
  • Comfort with data & alerts: If you’re comfortable responding to trend/alert data and adjusting your therapy, then more advanced systems help. If not, simpler may be better to avoid “alarm fatigue”.

“Closed-Loop / Automated Insulin Delivery”

A truly closed-loop system (also called an artificial pancreas) integrates three components:

  1. A continuous glucose monitor (CGM) that reads glucose every few minutes.
  2. An insulin pump that can automatically adjust insulin delivery (basal, sometimes bolus corrections) based on CGM data.
  3. A control algorithm/software that takes CGM data + pump data + user information and makes decisions on insulin dosing.
    In practice most widely available systems today are hybrid closed-loop: the algorithm adjusts basal delivery (and sometimes automatic correction boluses) but the user still typically must announce meals/carbohydrates and sometimes deliver a bolus. (Gluroo)

Compatible pump + CGM combinations

Here are specific examples of pumps and CGM systems that are compatible and used for AID/hybrid closed-loop.

Pump system (with algorithm name if any)

Compatible CGM(s)

Notes

Tandem t:slim X2 with “Control-IQ” algorithm

Dexcom G6 (all versions) + specific versions of G7 (Tandem Diabetes)

Widely used in USA. Hybrid closed-loop: predicts ~30 minutes ahead, can adjust basal and deliver automatic correction bolus. (Wikipedia)

Insulet Omnipod 5 (tubeless AID)

Dexcom G6 / G7 integration (per Dexcom compatibility list) (Dexcom)

A pod-based (tubeless) pump with AID functionality—flexibility of wearing pod instead of tubing.

Medtronic MiniMed 780G / 770G / 670G series

Medtronic’s own CGM (e.g., Guardian) and algorithm “SmartGuard” etc. (Wikipedia)

Established pump company; closed-loop algorithm included in 770G/780G.

YpsoPump (by Ypsomed) using the mylife CamAPS FX app/algorithm

Dexcom G6 or FreeStyle Libre 3 (depending on region) (mylife Diabetescare)

European-focused pump + algorithm option; smartphone-based control.

Things to check / considerations

  • CGM compatibility: Not all pumps support all CGMs; always check the specific model of CGM and pump version. For example Tan­dem states it supports Dexcom G6 fully, and specific versions of G7. (Tandem Diabetes)
  • Algorithm availability / regulatory approval: Even if pump + CGM are compatible, the closed-loop algorithm may not be approved in all countries/regions.
  • Region and market: A system available in the USA might not yet be approved in Europe/India (or might have a different name / version).
  • User involvement: Most systems still require user input (meal announcements, boluses) so they are hybrid rather than fully automatic.
  • Sensors & wearables: Sensor accuracy, sensor wear time, calibration requirements matter; they impact how well closed-loop works.
  • Backup plan & training: Given device complexities, having a backup plan (manual pump mode, extra supplies) and proper education/training is important.

closed-loop / automated insulin delivery (AID) options NOV 2025, showing which pumps pair with which CGMs, plus where they’re cleared/marketed (USA, Europe, India). “Closed-loop” here means hybrid closed loop unless noted.

United States (FDA-cleared)

  • Tandem t:slim X2 (Control-IQ) & Tandem Mobi  Dexcom G6 & G7. Hybrid closed loop via Control-IQ; G7 compatibility now live. (Tandem Diabetes)
    Link: tandemdiabetes.com (Tandem Diabetes)
  • Insulet Omnipod 5 (tubeless AID)  Dexcom G6 (G7/G6 pods rolling out; see EU note below). Indicated for T1D ≥2 yrs and T2D adults. (Omnipod)
    Link: insulet.com / omnipod.com. (Insulet)
  • Medtronic MiniMed 780G  Guardian™ 4 (and new Simplera Sync™ in EU first). FDA cleared April–May 2023. (Medtronic News)
    Link: medtronicdiabetes.com. (medtronic.com)
  • Beta Bionics iLet (Bionic Pancreas) Dexcom G6. FDA-cleared 2023; focuses on minimal carb entry (insulin-only system). (investors.betabionics.com)
    Link: betabionics.com (company site hosts updates/FAQs).

Interoperable controller (app):

  • Tidepool Loop (FDA-cleared iAGC app) works with iCGMs (e.g., Dexcom) and ACE-labeled pumps as partners come online; commercial pump partners are rolling out gradually. (accessdata.fda.gov)
    Link: tidepool.org/tidepool-loop. (tidepool.org)

Europe (CE-marked / marketed)

  • Insulet Omnipod 5  Dexcom G6 and, in many EU countries, Abbott FreeStyle Libre 2 Plus (first tubeless AID to integrate with both brands). Also G7-compatible pods now appearing by market. (Insulet Corporation)
    Link: omnipod.com (region selector). (Omnipod)
  • Medtronic MiniMed 780G  Guardian™ 4 (no fingersticks); Simplera Sync™ sensor EU launch underway. (Medtronic Diabetes)
    Link: medtronic-diabetes.com (EU). (Medtronic Diabetes)
  • Ypsomed mylife YpsoPump + CamAPS FX app  Dexcom G6 or FreeStyle Libre 3 / 3 Plus (region/OS dependent). Smartphone-based AID. (mylife Diabetescare)
    Link: mylife-diabetescare.com (mylife Loop). (mylife Diabetescare)
  • Diabeloop DBLG1 (algorithm) + pumps:
    • Roche Accu-Chek Insight + Dexcom G6 (pre-filled cartridge pump; adult indications). (assets.cwp.roche.com)
    • ViCentra Kaleido + Dexcom G6. (hellokaleido.com)
    • SOOIL Dana-i + Dexcom G6 (country rollouts vary). (Diabeloop)
    Link: diabeloop.com; roche.com/diabetes-care; hellokaleido.com; sooil.com. (Diabeloop)
  • Tandem t:slim X2 (Control-IQ) Dexcom G6 & G7 (and in 2025: Abbott FreeStyle Libre 3 Plus compatibility announced in some markets). (Dexcom)
    Link: tandemdiabetes.com (EU country pages available). (Dexcom)

India (current on-the-ground reality)

  • Medtronic actively markets pumps/sensors in India; contact Medtronic Diabetes India for MiniMed 780G + Guardian™ 4 availability and onboarding. (medtronicdiabetes.com)
    Link: medtronic-diabetes.in (via Medtronic international contacts). (medtronicdiabetes.com)
  • Tandem and Insulet (Omnipod 5): official distribution in India is limited/not broadly established; some third-party sellers list hardware, but check regulatory approval, warranty, and service locally before considering. (No authoritative manufacturer announcement of India launches as of today.) (hospitalstore.com)
  • Ypsomed / CamAPS FX / Diabeloop: pockets of EU-only rollouts; confirm with local endocrinology centers or distributors for India-specific access.

Quick chooser (who pairs with whom?)

  • Dexcom G6/G7: Tandem (US/EU), Omnipod 5 (G6 everywhere; G7 in many regions), Diabeloop systems (G6), YpsoPump+CamAPS (G6). (Dexcom)
  • Abbott Libre 3 / 3 Plus: YpsoPump+CamAPS FX (EU; Android & iOS), Omnipod 5 (Libre 2 Plus in several EU markets), Tandem t:slim X2 (Libre 3 Plus announced in some regions). (mylife Diabetescare)
  • Medtronic Guardian 4 / Simplera Sync: Medtronic 780G only (proprietary pairing). (Medtronic Diabetes)

Availability, indications (age, T1D/T2D), and exact sensor versions vary by country and software version—always confirm the exact combo for your location.

.